|
| 36690068 | Phase Separation in Biology and Disease; Current Perspectives and Open Questions. | J Mol Biol | 2023 |
| 36690068 | Phase Separation in Biology and Disease; Current Perspectives and Open Questions. | J Mol Biol | 2023 |
| 35857479 | Transplanted organoids empower human preclinical assessment of drug candidate for the clinic. | Sci Adv | 2022 |
| 35857479 | Transplanted organoids empower human preclinical assessment of drug candidate for the clinic. | Sci Adv | 2022 |
| 34622097 | Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial Design. | Kidney Int Rep | 2021 |
| 34622097 | Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial Design. | Kidney Int Rep | 2021 |
| 31749913 | Discovery of a Potent and Selective TRPC5 Inhibitor, Efficacious in a Focal Segmental Glomerulosclerosis Model. | ACS Med Chem Lett | 2019 |
| 31749913 | Discovery of a Potent and Selective TRPC5 Inhibitor, Efficacious in a Focal Segmental Glomerulosclerosis Model. | ACS Med Chem Lett | 2019 |
| 25414803 | Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial. | Exp Hematol Oncol | 2014 |
| 25414803 | Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial. | Exp Hematol Oncol | 2014 |
| 23379595 | Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met. | J Med Chem | 2013 |
| 23379595 | Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met. | J Med Chem | 2013 |
| 21608528 | Discovery of a 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer. | J Med Chem | 2011 |
| 21608528 | Discovery of a 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer. | J Med Chem | 2011 |
| 19933904 | Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904. | J Clin Oncol | 2010 |
| 19933904 | Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904. | J Clin Oncol | 2010 |
| 20197467 | Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model. | Cancer Res | 2010 |
| 20145145 | MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. | Cancer Res | 2010 |
| 20489150 | Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. | Am J Pathol | 2010 |
| 20489150 | Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. | Am J Pathol | 2010 |
| 20145145 | MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. | Cancer Res | 2010 |
| 20197467 | Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model. | Cancer Res | 2010 |
| 19307505 | Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. | J Clin Oncol | 2009 |
| 19738074 | Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer. | Cancer Res | 2009 |
| 19307505 | Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. | J Clin Oncol | 2009 |
| 19107230 | A quantitative volumetric micro-computed tomography method to analyze lung tumors in genetically engineered mouse models. | Neoplasia | 2009 |
| 19789319 | Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. | Clin Cancer Res | 2009 |
| 19775282 | Down-regulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia. | Br J Pharmacol | 2009 |
| 19413997 | An inhibitor of Janus kinase 2 prevents polycythemia in mice. | Biochem Pharmacol | 2009 |
| 19903844 | De novo discovery of a gamma-secretase inhibitor response signature using a novel in vivo breast tumor model. | Cancer Res | 2009 |
| 19903844 | De novo discovery of a gamma-secretase inhibitor response signature using a novel in vivo breast tumor model. | Cancer Res | 2009 |
| 19789319 | Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. | Clin Cancer Res | 2009 |
| 19775282 | Down-regulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia. | Br J Pharmacol | 2009 |
| 19738074 | Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer. | Cancer Res | 2009 |
| 19413997 | An inhibitor of Janus kinase 2 prevents polycythemia in mice. | Biochem Pharmacol | 2009 |
| 19107230 | A quantitative volumetric micro-computed tomography method to analyze lung tumors in genetically engineered mouse models. | Neoplasia | 2009 |
| 17962510 | Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. | Blood | 2008 |
| 17962510 | Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. | Blood | 2008 |
| 18483262 | Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. | Cancer Res | 2008 |
| 18483262 | Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. | Cancer Res | 2008 |
| 16960145 | Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). | Blood | 2007 |
| 16960145 | Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). | Blood | 2007 |